KALA BIO announced that its CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal epithelial defect did not meet the primary endpoint of complete healing of PCED as measured by corneal fluorescein staining. The CHASE trial also failed to achieve statistical significance for key secondary efficacy endpoints and did not show any meaningful difference between either KPI-012 treatment arm and the placebo arm.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Kala Pharmaceuticals Sets Date for Annual Meeting
- Strategic Positioning and Trial Design Propel Kala Pharmaceuticals to ‘Buy’ Rating
- Kala Pharmaceuticals price target raised to $35 from $12 at H.C. Wainwright
- Kala Pharmaceuticals price target raised to $33 from $15 at Oppenheimer
- Kala Pharmaceuticals initiated with an Outperform at Mizuho